Literature DB >> 23331434

Alternate-day dosing with statins.

Frank I Marcus1, Adam J Baumgarten, William L Fritz, Paul E Nolan.   

Abstract

The duration of the cholesterol-lowering effect of statins is considerably longer than the duration of the pharmacokinetic half-life of these drugs. The long duration of pharmacologic effects provides the rational for the efficacy of intermittent dosing that provides nearly the equivalent low-density lipoprotein cholesterol reduction compared with daily dosing. Review of studies comparing alternate-day dosing with daily dosing of statins indicates that the magnitude of low-density lipoprotein cholesterol reduction with alternate-day dosing is nearly the same, with obvious cost savings. It is possible that the adverse effects of statins, such as myalgia or diabetes, may be related to the cumulative amount of drug ingested over time, and if so, the adverse effects may be decreased by alternate-day dosing.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331434     DOI: 10.1016/j.amjmed.2012.08.007

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?

Authors:  Marc-Andre Cornier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

2.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

Authors:  Warner M Mampuya; David Frid; Michael Rocco; Julie Huang; Danielle M Brennan; Stanley L Hazen; Leslie Cho
Journal:  Am Heart J       Date:  2013-08-05       Impact factor: 4.749

Review 3.  Evolocumab: Considerations for the Management of Hyperlipidemia.

Authors:  Barbara S Wiggins; Jeffrey Senfield; Helina Kassahun; Armando Lira; Ransi Somaratne
Journal:  Curr Atheroscler Rep       Date:  2018-03-06       Impact factor: 5.113

Review 4.  Statin intolerance: diagnosis and remedies.

Authors:  Angela Pirillo; Alberico Luigi Catapano
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

5.  Effects of intravenous glucose and lipids on innate immune cell activation in healthy, obese, and type 2 diabetic subjects.

Authors:  Peter Horvath; Stacy R Oliver; Frank P Zaldivar; Shlomit Radom-Aizik; Pietro R Galassetti
Journal:  Physiol Rep       Date:  2015-02-12

6.  Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention.

Authors:  Ashish Sarraju; Andrew Ward; Jiang Li; Areli Valencia; Latha Palaniappan; David Scheinker; Fatima Rodriguez
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

7.  Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice.

Authors:  Theodore Christou; Hesham R Omar; Roger Dimitrov
Journal:  Drugs R D       Date:  2014-12

8.  The Adherence Rate Threshold is Drug Specific.

Authors:  Melissa E Stauffer; Paul Hutson; Anna S Kaufman; Alan Morrison
Journal:  Drugs R D       Date:  2017-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.